Exenatide Pretreatment Improved Graft Function in Nonhuman Primate Islet Recipients Compared to Treatment after Transplant Only
Figure 1
(a) Fasting blood glucose monitoring of transplanted animals. (b) Average fasting blood glucose levels measured at day 5 posttransplant. Untreated animals showed elevated blood glucose levels by day 1 posttransplant, animals treated with exenatide after transplant only showed somewhat elevated blood glucose levels beginning at day 4 posttransplant, while animals treated with ATG/CSA/MMF or pre-treated with exenatide remained normoglycemic throughout the study period. In fact, two animals from the exenatide pre-treatment group remained normoglycemic up to 435 days subsequent to transplant.
